Background: Screening and Brief Interventions for alcohol are an effective public health measure to tackle alcohol-related harm, however relatively few countries across the European Union (EU) have implemented them widely. This may be due to a lack of understanding of the specific financial implications of such policies within each country. Methods: A novel 'meta-modelling' approach was developed based on previous SBI cost-effectiveness models for four EU countries. Data were collected on the key factors which drive cost-effectiveness for all 28 EU countries (mean per capita alcohol consumption, proportion of the population to be screened over a 10-year SBI programme; per capita alcohol-attributable mortality; per capita alcohol-attributable morbidity; mean cost of an alcohol-related hospitalisation and mean SBI-delivery staff cost). Regression analysis was used to fit two meta-models estimating net programme costs and Quality-Adjusted Life Years (QALYs) gained, to calculate cost-effectiveness estimates specific to each EU country. Results: Costs are dependent upon the proportion of the population covered by the screening programme, the country-specific per capita mortality and morbidity rate and the country-specific costs of GP care and hospitalisation. QALYs depend on the proportion of the population screened and per capita alcohol consumption. Despite large inter-country variability in factor values, SBI programmes are likely to be cost-effective in 24 out of 28 EU countries and cost-saving in 50% of countries. Conclusion: Implementing national programmes of SBI in primary health care would be a cost-effective means of reducing alcohol-attributable morbidity and deaths in almost all countries of the EU.
Background: Screening and Brief Interventions for alcohol are an effective public health measure to tackle alcohol-related harm, however relatively few countries across the European Union (EU) have implemented them widely. This may be due to a lack of understanding of the specific financial implications of such policies within each country. Methods: A novel 'meta-modelling' approach was developed based on previous SBI cost-effectiveness models for four EU countries. Data were collected on the key factors which drive cost-effectiveness for all 28 EU countries (mean per capita alcohol consumption, proportion of the population to be screened over a 10-year SBI programme; per capita alcohol-attributable mortality; per capita alcohol-attributable morbidity; mean cost of an alcohol-related hospitalisation and mean SBI-delivery staff cost). Regression analysis was used to fit two meta-models estimating net programme costs and Quality-Adjusted Life Years (QALYs) gained, to calculate cost-effectiveness estimates specific to each EU country. Results: Costs are dependent upon the proportion of the population covered by the screening programme, the country-specific per capita mortality and morbidity rate and the country-specific costs of GP care and hospitalisation. QALYs depend on the proportion of the population screened and per capita alcohol consumption. Despite large inter-country variability in factor values, SBI programmes are likely to be cost-effective in 24 out of 28 EU countries and cost-saving in 50% of countries. Conclusion: Implementing national programmes of SBI in primary health care would be a cost-effective means of reducing alcohol-attributable morbidity and deaths in almost all countries of the EU.
Authors: Jürgen Rehm; Peter Anderson; Jose Angel Arbesu Prieto; Iain Armstrong; Henri-Jean Aubin; Michael Bachmann; Nuria Bastida Bastus; Carlos Brotons; Robyn Burton; Manuel Cardoso; Joan Colom; Daniel Duprez; Gerrit Gmel; Antoni Gual; Ludwig Kraus; Reinhold Kreutz; Helena Liira; Jakob Manthey; Lars Møller; Ľubomír Okruhlica; Michael Roerecke; Emanuele Scafato; Bernd Schulte; Lidia Segura-Garcia; Kevin David Shield; Cristina Sierra; Konstantin Vyshinskiy; Marcin Wojnar; José Zarco Journal: BMC Med Date: 2017-09-28 Impact factor: 8.775
Authors: Aashna Uppal; Olivia Oxlade; Ntwali Placide Nsengiyumva; Dieynaba S N'Diaye; Gonzalo G Alvarez; Kevin Schwartzman Journal: BMC Public Health Date: 2021-02-03 Impact factor: 3.295
Authors: Hugo López-Pelayo; Silvia Matrai; Mercè Balcells-Olivero; Eugènia Campeny; Fleur Braddick; Matthijs G Bossong; Olga S Cruz; Paolo Deluca; Geert Dom; Daniel Feingold; Tom P Freeman; Pablo Guzman; Chandni Hindocha; Brian C Kelly; Nienke Liebregts; Valentina Lorenzetti; Jakob Manthey; João Matias; Clara Oliveras; Maria Teresa Pons; Jürgen Rehm; Moritz Rosenkranz; Zoe Swithenbank; Luc van Deurse; Julian Vicente; Mike Vuolo; Marcin Wojnar; Antoni Gual Journal: Front Psychiatry Date: 2021-05-20 Impact factor: 4.157